Image via Yahoo Finance
Last updated
Gilead Sciences: Ma Activity
Gilead Sciences acquires Tubulis GmbH for $3.15B to expand oncology portfolio
Source: Yahoo Finance
The leadership read
Consolidation of this kind shifts demand toward integration and transformation leadership bench strength in biotech & pharma.
Market context: The wider read — a Talent Market Index of 111.1 (Hot), up 5.2 month-on-month — shows Americas signal flow rising (+6.3pts).
Gilead Sciences: 1 signal in the last 90 days — in line with the Biotech & Pharma median of 1 across 24 tracked companies; 0.2% of MitchelLake's Asia signal flow; 3 tracked across 62 days.
MitchelLake in this thematic
Also at Gilead Sciences →
More signals across Biotech & Pharma
Ma Activity · Americas
Biogen →Biogen announced and closed acquisition of Apellis Pharmaceuticals (immunology and rare diseases) in May 2026, and has just announced a second acquisition of an undisclosed company for $1 billion.
Ma Activity · Americas
Bora Pharmaceuticals →Bora Group announced acquisition of MacroGenics' GMP manufacturing operations and CDMO business for US$122.5 million plus up to US$5 million contingent consideration. Includes biologics manufacturing facility in Rockville, Maryland with substantial backlog.
Capital Raising · Americas
BridgeBio →BridgeBio secured funding to support drug launch; United Airlines made an investment into the cell therapy space
Partnership · Americas
Basecamp Research →Basecamp Research integrated its EDEN antibiotic and vaccine design models into Claude Science, enabling scientists to design antibiotics and prioritize vaccine targets through Claude's interface.
Product Launch · Americas
Bota Biosciences →Bota Biosciences released Biology Protocol Language (BPL) and BPL-COGEN, a compiler-verified protocol language and generation pipeline for AI-driven biomanufacturing, announced on bioRxiv.
Product Launch · Americas
Neurocrine Biosciences →Neurocrine presented CRENESSITY clinical data at ENDO 2026 demonstrating hormone normalization in classic CAH and two-year cardiometabolic and bone health outcomes in adults.
Intelligence powered by Autonodal ↗